Aastrom builds on stem cell success in heart failure
This article was originally published in Scrip
Executive Summary
Aastrom Bioscience's stem cell treatment ixmyelocel-T has improved heart function in a Phase IIa study in patients with heart failure due to dilated cardiomyopathy.